Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial - Trial NCT06356597
Access comprehensive clinical trial information for NCT06356597 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jing-yuan Fang, MD, Ph. D and is currently Recruiting. The study focuses on Colorectal Cancer. Target enrollment is 25 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Jing-yuan Fang, MD, Ph. D
Shanghai Jiao Tong University School of Medicine
Timeline & Enrollment
Phase 2
Apr 01, 2024
Dec 12, 2027
Primary Outcome
objective response rate
Summary
The aim of this study is to evaluate the efficacy and safety of Tislelizumab with
 Fruquintinib, Metronidazole treatment in MSS/MSI-L advanced colorectal cancer patients with
 high abundance of Fusobacterium nucleatum in a single arm Phase II clinical.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06356597
Non-Device Trial